Cargando…

Ovarian cysts in women receiving tamoxifen for breast cancer

Tamoxifen is a nonsteroidal anti-oestrogen with gynaecological side-effects. Only recently, ovarian cyst formation during tamoxifen treatment has been reported. The present study aimed to evaluate patient-related parameters that determine ovarian cyst formation in women using tamoxifen for breast ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mourits, M J E, Vries, E G E de, Willemse, P H B, Hoor, K A ten, Hollema, H, Sluiter, W J, Bruijn, H W A de
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362821/ https://www.ncbi.nlm.nih.gov/pubmed/10206289 http://dx.doi.org/10.1038/sj.bjc.6690280

Ejemplares similares

Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy
por: Mourits, M J, et al.
Publicado: (2002)

DNA topoisomerase IIα and -β expression in human ovarian cancer
por: Withoff, S, et al.
Publicado: (1999)

The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer
por: de Graeff, P, et al.
Publicado: (2008)

Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer
por: Bos, A M E, et al.
Publicado: (2000)

Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity
por: Gooden, M J M, et al.
Publicado: (2014)

Potential Target Antigens for a Universal Vaccine in Epithelial Ovarian Cancer
por: Vermeij, Renee, et al.
Publicado: (2010)

Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: Pooled results from three countries
por: Jones, Michael E, et al.
Publicado: (2012)

Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer
por: Leffers, N, et al.
Publicado: (2010)

Development and characterization of a tamoxifen-resistant breast carcinoma xenograft
por: Naundorf, H, et al.
Publicado: (2000)

The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer
por: Dowsett, M, et al.
Publicado: (1999)

Reply: The classification of p53 immunohistochemical staining results and patient outcome in ovarian cancer
por: de Graeff, P, et al.
Publicado: (2007)

Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women
por: Daidone, M G, et al.
Publicado: (2000)

Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer
por: Foekens, J A, et al.
Publicado: (1999)

Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL
por: Meijer, A, et al.
Publicado: (2013)

Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin
por: Jong, R S de, et al.
Publicado: (1999)

A phase I and pharmacokinetic study of intraperitoneal topotecan
por: Hofstra, L S, et al.
Publicado: (2001)

The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation
por: Paju, A, et al.
Publicado: (2001)

The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma
por: McClay, E F, et al.
Publicado: (2000)

Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy.
por: van der Zee, A. G., et al.
Publicado: (1992)

Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies
por: de Graeff, P, et al.
Publicado: (2006)

Tamoxifen inhibits the biosynthesis of inositolphosphorylceramide in Leishmania
por: Trinconi, Cristiana T., et al.
Publicado: (2018)

First do no harm: extending the debate on the provision of preventive tamoxifen
por: Will, B P, et al.
Publicado: (2001)

Rising serum values of beta-subunit human chorionic gonadotrophin (hCG) in patients with progressive vulvar carcinomas.
por: de Bruijn, H. W., et al.
Publicado: (1997)

In squamous cell carcinoma of the vulva, overexpression of p53 is a late event and neither p53 nor mdm2 expression is a useful marker to predict lymph node metastases
por: Emanuels, A G, et al.
Publicado: (1999)

Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours
por: MacCallum, J, et al.
Publicado: (2000)

The effect of tamoxifen therapy on the endometrium and ovarian cyst formation in patients with breast cancer
por: Lee, Seul, et al.
Publicado: (2018)

Which antidepressant agent can be used in patients receiving tamoxifen?
por: Maamri, A., et al.
Publicado: (2021)

Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women
por: Marttunen, M B, et al.
Publicado: (2001)

Bone mineral content of women receiving tamoxifen for mastalgia.
por: Fentiman, I. S., et al.
Publicado: (1989)

Modulation of oestrone sulphate formation and hydrolysis in breast cancer cells by breast cyst fluid from British and Hungarian women
por: Purohit, A, et al.
Publicado: (2000)

Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen
por: Jansen, Maurice P.H.M., et al.
Publicado: (2016)

Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2
por: Ligtenberg, M J L, et al.
Publicado: (1999)

Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer
por: Gelderblom, H, et al.
Publicado: (2001)

Tamoxifen and Ovarian Function
por: Berliere, Martine, et al.
Publicado: (2013)

Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen
por: van Nuland, M., et al.
Publicado: (2018)

Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line
por: Parisot, J P, et al.
Publicado: (1999)

Pain evaluation during gynaecological surveillance in women with Lynch syndrome
por: Helder-Woolderink, Jorien, et al.
Publicado: (2016)

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial
por: Trialists' Group, The ATAC
Publicado: (2001)

Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial
por: Windbichler, G H, et al.
Publicado: (2000)

Ovarian cancer risk in premenopausal and perimenopausal women treated with Tamoxifen: a case–control study
por: Swerdlow, A J, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_rppiblcpccicmbua0lu0mp3b20